<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Infection</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/91427003-DFB6-48F9-848A-32A456E1C00F"><gtr:id>91427003-DFB6-48F9-848A-32A456E1C00F</gtr:id><gtr:name>Royal Free Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/BFB9BCDC-7FA3-444E-8569-5D6A13098B64"><gtr:id>BFB9BCDC-7FA3-444E-8569-5D6A13098B64</gtr:id><gtr:firstName>Dimitra</gtr:firstName><gtr:surname>Peppa</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0902009"><gtr:id>74E3B9E3-0C08-48C2-9D22-1F4F642294D5</gtr:id><gtr:title>Pathogenic Interaction between Natural Killer (NK) and T cells in chronic Hepatitis B Virus Infection</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0902009</gtr:grantReference><gtr:abstractText>Hepatitis B virus (HBV) persistently infects more than 400 million people worldwide. Chronic (longterm) infection carries a risk of serious complications including severe liver disease and liver cancer and is responsible for more than 1 million deaths per year. The body combats the virus using a number of specialised cell types. The main cell type fighting the virus, called the T cell, is severely impaired in chronic infection. In this study we will be looking at the ability of another type of cell called Natural Killer (NK) cell, to kill the beneficial T cells. NK cells have already been shown to be able to cause liver damage in viral hepatitis and we have found increased numbers in patients with chronic hepatitis B. Malfunctioning NK cells may also attack healthy T cells, causing chronic disease instead of fighting it. The purpose of this study is to identify the possible NK cell-mediated death pathways leading to T cell ?exhaustion?. We will use blood and liver samples obtained during routine clinical care of patients infected with HBV following informed consent. Blocking these harmful death pathways will boost the immune system leading to improved viral control and prevention of chronic disease and liver damage.</gtr:abstractText><gtr:technicalSummary>Aims and Objectives: Accumulating data indicate that Natural Killer (NK) cells play an important role in shaping adaptive immunity. Our group has demonstrated an enrichment of activated CD56bright NK cells expressing the TNF-related apoptosis-inducing ligand (TRAIL) in the HBV-infected liver and identified a role for natural killer (NK) cells in amplifying liver damage through the TRAIL pathway (Dunn JEM 2007). Recent studies and preliminary data have highlighted the potential for NK cells to delete autologous T cells when T cell activation overrides the physiological protection against this. We postulate that activated HBV-specific T cells become susceptible to deletion by pathogenic intrahepatic NK cells in the setting of the inflamed HBV-infected liver. NK cell-mediated killing could thereby constitute a novel mechanism contributing to the profound virus-specific T cell depletion in chronic HBV infection. We aim to investigate whether NK and virus-specific T cells upregulate the appropriate receptor-ligand pairs to allow NK cell-mediated T cell deletion in active HBV infection.
Design and Methodology: We will concentrate on TRAIL and NKG2D as potential pathways of deletion and assess the level of expression of NK and T death receptor-ligand pairs according to disease activity. Using surplus tissue from diagnostic liver biopsies or explants, we will investigate whether there is enhanced expression of death receptor-ligand pairs in the intrahepatic compared to the peripheral compartment. Functional experiments with blocking antibodies and NK cell depletion will allow us to determine the capacity of NK cells to kill autologous virus-specific T cells from patients with different disease profiles, and to investigate whether HBV-specific T cells are more susceptible than T cells of other specificities in the same patients. A longitudinal sub-study of patients commencing antiviral therapy will examine its potential to reverse any pathogenic NK-T cell interactions.
Scientific and medical opportunities: Chronic infection with HBV causes cirrhosis and hepatocellular carcinoma, remaining one of the top ten causes of mortality worldwide. This work could lead to the development of agents to block pathogenic NK cell interactions at the time of therapeutic vaccination, enabling reconstitution of sustained virus-specific T cell responses whilst limiting liver damage. Insights from this study of NK cells in chronic HBV infection could be applied to other hepatotropic pathogens (HCV, malaria) and tumours and will extend knowledge of innate-adaptive immune interactions.</gtr:technicalSummary><gtr:fund><gtr:end>2013-03-15</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>244461</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Royal Free Hospital</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Sample collection</gtr:description><gtr:id>8F5CD84F-ECDC-44E9-B54C-CE0E77CE1A8B</gtr:id><gtr:impact>Dunn et al Gastro 2009
Peppa et al Plos Pathogens 2010
Nebbia et al Plos one 2012
Peppa et al JEM accepted for publication 2012</gtr:impact><gtr:outcomeId>LZnDb875BtZ-1</gtr:outcomeId><gtr:partnerContribution>access to clinical samples</gtr:partnerContribution><gtr:piContribution>access to data</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Sexual Health &amp; HIV</gtr:department><gtr:description>Sample collection</gtr:description><gtr:id>B228236F-CCD1-481F-AD10-FD728169D627</gtr:id><gtr:impact>Dunn et al Gastro 2009
Peppa et al Plos Pathogens 2010
Nebbia et al Plos one 2012
Peppa et al JEM accepted for publication 2012</gtr:impact><gtr:outcomeId>LZnDb875BtZ-2</gtr:outcomeId><gtr:partnerContribution>access to clinical samples</gtr:partnerContribution><gtr:piContribution>access to data</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Birmingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>immunohistochemistry/immunofluorescence</gtr:description><gtr:id>1A5E276D-719D-4114-B384-5FC7AF3CD023</gtr:id><gtr:impact>recent JEM paper in press</gtr:impact><gtr:outcomeId>FJTNG6UwYyV-1</gtr:outcomeId><gtr:partnerContribution>expertise in liver tissue immunohistochemistry</gtr:partnerContribution><gtr:piContribution>provision of reagents</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>liver biopsy specimens</gtr:description><gtr:id>D0C1FF81-B8A7-4928-9A58-9B49D236D752</gtr:id><gtr:impact>recent publication in press</gtr:impact><gtr:outcomeId>K5zGWPkgESe-1</gtr:outcomeId><gtr:partnerContribution>recent publication Peppa et al PLoS Pathogens in press</gtr:partnerContribution><gtr:piContribution>access to data, equipment and training of staff</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>co-culture experiments</gtr:description><gtr:id>DFB31A62-37FD-429D-9C3B-31428C690CD1</gtr:id><gtr:impact>manuscipt in preparation</gtr:impact><gtr:outcomeId>iswNZFxLC4t-1</gtr:outcomeId><gtr:partnerContribution>new system of screening for ligand expression</gtr:partnerContribution><gtr:piContribution>PBMC samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MRC at UCL Centenary Science Fair seminar series</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>52F582C1-EA4F-492F-B799-BEA471A40CB2</gtr:id><gtr:impact>Lay audience and young children

young children were very keen to learn more about basic laboratory skills</gtr:impact><gtr:outcomeId>PPNnhNowqzb</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Talk: Tuesday 12 November, 1400- 1500 Barnett Christie Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8D14C065-1930-4D42-9619-A3B89C7783FD</gtr:id><gtr:impact>I was an invited speaker at the Action on Infection Federation of Infection Societies Conference 2013. I discussed the findings of my PhD work and recent publication findings.</gtr:impact><gtr:outcomeId>56df40f6ab0194.20513286</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travel Grant Award, International Meeting The Molecular Biology of Hepatitis B Virus (HBV)</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>A067454E-9A2B-437D-93D8-1038C8BA5F7A</gtr:id><gtr:outcomeId>oAbXv7B9aLP0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>13th meeting of the Society for Natural Immunity April 20-24, 2012, Asilomar, CA</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Society for Natural Immunity</gtr:fundingOrg><gtr:id>3DDE9DB7-FFD6-4921-992D-6D283042D5BA</gtr:id><gtr:outcomeId>hEKzjNpMZVr</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC individual Travel grants</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>Project code: GCXA</gtr:fundingRef><gtr:id>E9EB451D-C385-4D0F-A969-00B10C12CE19</gtr:id><gtr:outcomeId>eY2dvuY8kCF</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>530</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>International Meeting The Molecular Biology of Hepatitis B Virus (HBV), Oxford, UK 2012</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>National Institutes of Health (NIH)</gtr:fundingOrg><gtr:id>2D5C5306-23E4-44B2-9145-802F71A69283</gtr:id><gtr:outcomeId>nyfG1R71g8m</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>86FFC486-CBEC-4A5E-B4D6-E498EA23C09A</gtr:id><gtr:title>Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9a63cf2874b64c177ac34d7c2bbbe046"><gtr:id>9a63cf2874b64c177ac34d7c2bbbe046</gtr:id><gtr:otherNames>Gill US</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>5aa58f0c87f403.69754239</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC9BF95C-317F-42AD-8257-AD67B0E5002F</gtr:id><gtr:title>Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7899ea19d47dbd497f60b7b9b5ecc23c"><gtr:id>7899ea19d47dbd497f60b7b9b5ecc23c</gtr:id><gtr:otherNames>Micco L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>pm_14725_25_23046671</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF2A46D6-D931-4F9E-9374-F5F835546C25</gtr:id><gtr:title>Immune responses in hepatitis B: a brief overview</gtr:title><gtr:parentPublicationTitle>Viral hepatitis in practice</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66162d227f4ffe2ecbd90d83e69270c6"><gtr:id>66162d227f4ffe2ecbd90d83e69270c6</gtr:id><gtr:otherNames>Mala K Maini, Nicholas Easom, Dimitra Peppa and Abhishek Das</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>p5wUMssu4pr</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4F26E629-ADD0-4F7D-B376-FFAC803E5534</gtr:id><gtr:title>Upregulation of the Tim-3/galectin-9 pathway of T cell exhaustion in chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76c7e7f6d167384202514d2509288582"><gtr:id>76c7e7f6d167384202514d2509288582</gtr:id><gtr:otherNames>Nebbia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>RHEM5tnD3Y2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>684625F4-7E18-46DA-A860-F0F67D2E10FA</gtr:id><gtr:title>Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a204313f8b28cda4fa83ec02826e3c1c"><gtr:id>a204313f8b28cda4fa83ec02826e3c1c</gtr:id><gtr:otherNames>Peppa D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>fHK1K3YQBeX</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8AE88FA9-849D-44BC-93E5-82B37A1A0B4C</gtr:id><gtr:title>Defective natural killer cell anti-viral capacity in paediatric HBV infection.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/52960d2a25ccfec0c8413c520692cebd"><gtr:id>52960d2a25ccfec0c8413c520692cebd</gtr:id><gtr:otherNames>Heiberg IL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>54647b12ae8609.77586512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0865E303-ED3D-44F9-B7E3-04100861F798</gtr:id><gtr:title>CXCR6 marks a novel subset of T-bet(lo)Eomes(hi) natural killer cells residing in human liver.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27cb1d45499e39ae5eaa8757209fada3"><gtr:id>27cb1d45499e39ae5eaa8757209fada3</gtr:id><gtr:otherNames>Stegmann KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa58f3f5c9245.31910018</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F1849F4F-1E6F-429D-8D67-BA1288B3ACF5</gtr:id><gtr:title>Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76183b379cf986c149f52dd20886bd52"><gtr:id>76183b379cf986c149f52dd20886bd52</gtr:id><gtr:otherNames>Schurich A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>DVBpSLuCGKL</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FCFD9AA3-0FFB-4BEB-A167-8CA58E36A956</gtr:id><gtr:title>IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d10e93066e667cdd76d1e66f25e5b519"><gtr:id>d10e93066e667cdd76d1e66f25e5b519</gtr:id><gtr:otherNames>Das A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>pm_14725_25_22972930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>798CA8C4-90A3-42FF-BBC4-2FD7B715BBB6</gtr:id><gtr:title>NK cells: a double-edged sword in chronic hepatitis B virus infection.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc11615f37418526ac40b69bc86fc1a4"><gtr:id>dc11615f37418526ac40b69bc86fc1a4</gtr:id><gtr:otherNames>Maini MK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>pm_14725_25_23459859</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E875201E-54BA-41DD-8719-D5618B18272D</gtr:id><gtr:title>Up-regulation of a death receptor renders antiviral T cells susceptible to NK cell-mediated deletion.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a204313f8b28cda4fa83ec02826e3c1c"><gtr:id>a204313f8b28cda4fa83ec02826e3c1c</gtr:id><gtr:otherNames>Peppa D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>KgP4HbL3je2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE0EF703-7520-4681-9058-2DF7656FA476</gtr:id><gtr:title>Systemic inflammation and residual viraemia in HIV-positive adults on protease inhibitor monotherapy: a cross-sectional study.</gtr:title><gtr:parentPublicationTitle>BMC infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d40f983c26b14cc725a711fb9036e4d"><gtr:id>5d40f983c26b14cc725a711fb9036e4d</gtr:id><gtr:otherNames>Arenas-Pinto A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2334</gtr:issn><gtr:outcomeId>56df35307f4428.12082465</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B1AA4B07-4076-4C57-B69C-94ED6B798BE7</gtr:id><gtr:title>Hepatitis B infection: current concepts and future challenges.</gtr:title><gtr:parentPublicationTitle>QJM : monthly journal of the Association of Physicians</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76c7e7f6d167384202514d2509288582"><gtr:id>76c7e7f6d167384202514d2509288582</gtr:id><gtr:otherNames>Nebbia G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1460-2393</gtr:issn><gtr:outcomeId>pm_14725_25_22252919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>095EAEB5-D38F-42E4-AE35-56CCE5832A14</gtr:id><gtr:title>Pathogenesis of hepatitis B virus infection and potential for new therapies.</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a204313f8b28cda4fa83ec02826e3c1c"><gtr:id>a204313f8b28cda4fa83ec02826e3c1c</gtr:id><gtr:otherNames>Peppa D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn><gtr:outcomeId>aQgDvcWdWgL</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0902009</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>